Search Results

Applied BioCode announced the retirement of Chris Bernard as Chief Executive Officer.

Applied BioCode now offers STI + Resistance Panel on the BioCode® MDx-3000 system for research use only (RUO).

Applied BioCode now offers Fungal Panel on the BioCode® MDx-3000 system for research use only.

The Bruker Applied Mass Spectrometry Division is showcasing some of its latest innovations at ASMS 2024.

Applied BioCode announced today that Chris Bernard has been appointed as their new Chief Executive Officer (CEO).

Applied DNA Sciences, Inc. announced that its molecular diagnostics subsidiary, Applied DNA Clinical Labs, LLC, will utilize the GenXys Health Care Systems suite of clinical decision support software for interpretation and reporting of ADCL’s New York State Department of Health-approved TR8™ pharmacogenomic test.

Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced that on May 9, 2024, it received a notification letter from the Listing Qualifications Department of the Nasdaq Stock Market informing the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2).

Applied DNA Sciences, Inc., a leader in PCR-based DNA technologies, announced the pricing of a public offering with gross proceeds to the Company expected to be approximately $12.0 million, before deducting placement agent fees and other estimated expenses payable by the Company.

Applied BioCode announced today that it has received Emergency Use Authorization (EUA) from the US FDA for its BioCode® CoV-2 Flu Plus Assay.

Applied DNA Sciences, Inc. (NASDAQ:APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today announced that the New York State Department of Health (“NYSDOH”) approved the Company’s TR8™ PGx (“TR8") pharmacogenomic (PGx) testing service.